Variability in lipid measurements can have major impact on treatment during secondary prevention

Eur J Prev Cardiol. 2022 Feb 9;28(18):e4-e5. doi: 10.1093/eurjpc/zwaa004.

Authors

Victor J van den Berg¹, Maxime M Vroegindewey¹, Jeanine E Roeters van Lennep², Victor A W M Umans³, Jaap W Deckers¹, K Martijn Akkerhuis¹, Isabella Kardys¹, Eric Boersma¹; BIOMArCS investigators

Affiliations

¹ Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Room Na317, RG-5, PO Box 2040, 3000 CA Rotterdam, the Netherlands.
² Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
³ Department of Cardiology, Northwest Clinics, Wilhelminalaan 12, 1815 JD, Alkmaar, the Netherlands.

PMID: 33624006
DOI: 10.1093/eurjpc/zwaa004

No abstract available

Keywords: Acute coronary syndrome; Biological variation; LDL; Lipids; Lipoproteins; Myocardial infarction; Population; Statins.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cholesterol, LDL
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Secondary Prevention

Substances

Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors